Compounds / Tissue Repair / B7-33

B7-33

B7-33 (Single-chain Relaxin Peptide Analogue)

Tissue RepairFDA: Not approved — investigational

Overview

Developed at the Florey Institute. Preclinical studies show potent anti-fibrotic effects in cardiac and renal fibrosis models with reduced hypotensive side effects vs native relaxin-2.

Mechanism of Action

Selectively activates RXFP1 as a biased agonist, engaging anti-fibrotic pERK1/2 signaling while minimizing cAMP-mediated vasodilation. Single B-chain design retains therapeutic anti-fibrotic activity.

Molecular Profile

Molecular weight

~3500 Da

Key Research Findings

Biased RXFP1 agonist; reduces cardiac and renal fibrosis; less hypotension than relaxin-2; investigational.

Published Research

Science Signaling

B7-33 as a biased RXFP1 agonist

View source

FASEB Journal

B7-33 reduces fibrosis and cardiac remodeling

View source

Related Tissue Repair Compounds

BPC-157 TB-500 AHK-Cu KPV MGF PEG-MGF

Clinical Guidance

Research data is not a treatment plan. If you are considering B7-33, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running B7-33? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals